Synergy Pharmaceuticals (SGYP.OB) Completes Private Placement – Raises $8.6 Million in Common Stock Financing
Synergy Pharmaceuticals, Inc., a leading biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases, recently announced that the company has completed a private placement, raising an aggregate $8.6 million through the sale of common stock at a price of $0.70 per share. The proceeds from the private placement will be used to fund a Phase IIa clinical trial of Synergy’s SP-304 for chronic constipation, which is scheduled to commence in the first quarter of 2010. SP-304, a synthetic analog of the human gastrointestinal hormone uroguanylin, recently finished a Phase I clinical trial in volunteers.…